Barry J. Byrne

B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study

T. Conlon, N. Clément, M. Corti, 2014, Molecular therapy. Methods & clinical development.

Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

T. Conlon, B. Byrne, I. Tuna, 2017, Human gene therapy. Clinical development.

Phase I / II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase ( rAAV 1-CMV-GAA ) Gene Vector in Patients with Pompe Disease

T. Conlon, C. Mah, M. Corti, 2014 .

Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies

C. Tifft, M. Corti, Precilla D’Souza, 2023, The Journal of clinical investigation.

Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines

M. Corti, Prasad D. Trivedi, Barry J. Byrne, 2023, Viruses.

B cell focused transient immune suppression protocol for efficient AAV readministration to the liver

M. Corti, D. Markusic, Moanaro Biswas, 2024, Molecular therapy. Methods & clinical development.

Adeno-associated virus-mediated gene therapy for metabolic myopathy.

B. Byrne, Angela L McCall, C. Mah, 2013, Human gene therapy.

Expression of erythropoietin in cats treated with a recombinant adeno-associated viral vector.

B. Byrne, J. MacLeod, K. Cahill, 2005, American journal of veterinary research.

Tolerance Induction to Cytoplasmic \(\beta\)-galactosidase by Hepatic Aav Gene Transfer — Implications for Antigen Presentation and Immunotoxicity Tolerance Induction to Cytoplasmic B-galactosidase by Hepatic Aav Gene Transfer — Implications for Antigen Presentation and Immunotoxicity

R. Herzog, D. Markusic, C. Terhorst, 2022 .